PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.08%
G&A change of 6.08% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
0.73%
Other expenses change of 0.73% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
5.73%
Operating expenses growth while Biotechnology reduces costs. Peter Lynch would examine differences.
5.73%
Total costs growth while Biotechnology reduces costs. Peter Lynch would examine differences.
3.59%
Interest expense change of 3.59% versus flat Biotechnology costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
-5.73%
EBITDA decline while Biotechnology median is 2.95%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-5.73%
Operating income decline while Biotechnology median is 1.27%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.82%
Tax expense change of 4.82% versus flat Biotechnology. Walter Schloss would verify strategy.
-4.82%
Net income decline while Biotechnology median is 1.42%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-5.05%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-5.05%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.